|
|
Post by compound26 on Nov 16, 2015 16:23:28 GMT -5
Pursuant to this site, it appears Novolog will lose its patent in 2017. Could someone knowledgeable on this subject confirm whether this is true or not. If that is true, it appears there actually is not such big conflict of its RAA business for Novo to pick up Afrezza. This is especially the case giving Matt B's videos on Tresiba + Afrezza working extremely well. |
|
|
|
Post by mssciguy on Nov 16, 2015 16:29:43 GMT -5
Pursuant to this site, it appears Novolog will lose its patent in 2017. Could someone knowledgeable on this subject confirm whether this is true or not. If that is true, it appears there actually is not such big conflict of its RAA business for Novo to pick up Afrezza. This is especially the case giving Matt B's videos on Tresiba + Afrezza working extremely well. Funny, on another message board, Sanofi was referred to as Snafui --- not bad huh? (joke of the day for us longs)  would love to see interest from Novo  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 16, 2015 16:35:36 GMT -5
Ha-ha, I've had that happen with my auto spell too! Every time I type Sanofi, my spell check tries to correct it to: Snafu. Makes me laugh all the time. Oh, how I wish wasn't so and we were sitting at $12, where we should be!
|
|
|
|
Post by od on Nov 16, 2015 17:38:22 GMT -5
|
|
|
|
Post by rockstarrick on Nov 17, 2015 13:00:57 GMT -5
Pursuant to this site, it appears Novolog will lose its patent in 2017. Could someone knowledgeable on this subject confirm whether this is true or not. If that is true, it appears there actually is not such big conflict of its RAA business for Novo to pick up Afrezza. This is especially the case giving Matt B's videos on Tresiba + Afrezza working extremely well. Patent expiration dates: Novolog.... Insulin preparations containing NaCl Patent 5,866,538 Issued: February 2, 1999 Inventor(s): Norup; Elsebeth & Langkj.ae butted.r; Liselotte & Havelund; Svend Assignee(s): Novo Nordisk A/S Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed. Patent expiration dates: June 20, 2017 ✓ Drug product December 20, 2017 ✓ Pediatric exclusivity |
|
|
|
Post by trondisc on Nov 17, 2015 22:53:08 GMT -5
Pursuant to this site, it appears Novolog will lose its patent in 2017. Could someone knowledgeable on this subject confirm whether this is true or not. If that is true, it appears there actually is not such big conflict of its RAA business for Novo to pick up Afrezza. This is especially the case giving Matt B's videos on Tresiba + Afrezza working extremely well. Excellent thesis/theory & appreciate the posted link you found to connect the dots for the future (potentially)... |
|
|
|
Post by slapshot on Nov 17, 2015 23:40:59 GMT -5
Looks like you have pretty well confirmed the patent expiration from multiple sites. But to be official, these days, patents are good for 20 years from the earliest filing/priority date (assuming of course that patentees maintain the patent (with fees) and plus any additional time due to unreasonable prosecution resulting in an adjustment). USP 5866538 was effectively filed 6/20/1997 so therefore would expire 6/20/2017. I see no adjustment in the record so it will expire in 2017.
|
|
